CytomX and MD Anderson Cancer Center enter collaboration for Probody-enabled CAR-NK cell therapies
09-Nov-2015 -
CytomX Therapeutics, a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) ...
cancer
cancer immunotherapies
cell therapies
+4